A Phase 1/2 interventional study of PYC-001 in OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy and Hereditary Optic Atrophies, sponsored by PYC Therapeutics. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by PYC Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approximately 18 participants from Australia, New Zealand, and other APAC countries are expected to be enrolled, depending on safety review committee (SRC) throughout the course of the study.
Participants may be assigned to any of the following:
Three doses of 30ug PYC-001 at an interval of 12 weeks
Following completion of the 4 week safety review of the single 60ug of PYC-001 cohort, and if the 60 μg dose level is deemed safe by the SRC, the following cohorts will also be available:
This is a phase 1b open-label, randomized, single and repeat dose study to evaluate the safety and tolerability of IVT administered PYC-001 in participants with confirmed OPA1 mutation-associated ADOA.
The primary objective of this study is to gather safety data and determine the optimal dosing regimen for PYC-001.
The exploratory objectives of this study include evaluating the ocular structural and functional changes following multiple doses of IVT administered PYC-001. The PK profile of PYC-001 following multiple doses will also be assessed.
In this open-label study, PYC-001 will be injected in a single eye and ocular safety will be assessed in both eyes.
PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants must be of non- or if female participants are of childbearing potential, they must:
Male participants must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of 60ug of PYC-001 administered intravitreally
Drug: PYC-001
Up to 12 doses of 10ug PYC-001, administered intravitreally in 8 weeks interval.
Drug: PYC-001
Up to 12 doses of 10ug PYC-001, administered intravitreally in 12 weeks interval
Drug: PYC-001
Up to 12 doses of 30ug PYC-001, administered intravitreally in 8 weeks interval
Drug: PYC-001
Up to 12 doses of 30ug PYC-001, administered intravitreally in 12 weeks interval
Drug: PYC-001
Following SRC, Single dose participant can continue to receive Up to 12 doses of 60ug PYC-001, administered intravitreally at 12 weeks interval; alternatively, treatment naive participants can be enrolled (once SRC is complete) to receive up to 12 doses
Drug: PYC-001
PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally
[All Cohorts] Number of participants experiencing treatment emergent adverse events
The incidence, type, severity, and relationship of treatment emergent ocular and non-ocular adverse events and treatment-emergent Serious Adverse Events will be recorded. An AE is any untoward medical occurrence in a clinical study participant that either occurs during the study or, if present predose, worsens during the study, and which does not necessarily have to have a causal relationship with the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease associated with study participation, whether or not considered related to the study treatment.
Time frame: Up to 164 weeks
[All Cohorts] Changes from baseline in vital signs (heart rate)
Time frame: Up to 164 weeks
[All Cohorts] Changes from baseline in vital signs (systolic and diastolic blood pressure)
Time frame: Up to 164 weeks
[All Cohorts] Changes from baseline in vital signs (tympanic temperature)
Time frame: Up to 164 weeks
[All Cohorts] Changes from baseline in vital signs (respiratory rate)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in white blood cells (WBC), platelets, white blood cell count with differential neutrophil count, eosinophil count, basophil count, lymphocyte count, monocyte count
All measured in 10x\^9L
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in red blood cells
Units x 10\^12L
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in hemoglobin and mean corpuscular hemaglobin concentration
Units: grams per liter (g/L)
Time frame: Up to164 weeks
[All Cohorts] Change from baseline in mean corpuscular volume and mean platelet volume
measured in femtoliter (fL)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in hematocrit
Units: litres per litre (L/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in mean corpuscular hemoglobin
Units: picograms (pg)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in neutrophils, lymphocytes, monocytes, eosinophils, basophils and reticulocyte count
Units: %
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Alanine Transaminase, Alkaline Phosphatase, Aspartate aminotransferase, Creatine Phosphokinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase, Amylase and Lipase
Units: units/Liter (U/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Bilirubin (total, direct and indirect) and creatinine
Units: micromoles per liter (mcmol/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in protein, albumin, globulin and fibrinogen
Units:grams per liter (g/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphorous, Total Cholesterol, Triglyceride, HDL, LD. Uric Acid and Glucose
Units: millimoles per liter (mmol/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Anion Gap
Units: milliequivalents per liter (mEq/L)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Prothrombin Time and Partial Thromboplastin Time, Activated (APTT)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in Prothrombin Time (INR)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in urinalysis (Protein, glucose, ketones, blood, bilirubin, leucocyte esterase and nitrites
Presence (positive, negative, trace) captured
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in urinalysis (pH)
Time frame: Up to 164 weeks
[All Cohorts] Change from baseline in urinalysis (specific gravity)
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Best Corrected Visual Acuity (BCVA)/ High Contrast Visual Acuity (HCVA) and Low Contrast Visual Acuity (LCVA) scores
Early Treatment Diabetic Retinopathy Study (ETDRS) optotypes used, letter score will be captured for BCVA/HCVa and LCVA.
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Visual field sensitivity by photopic static perimetry
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in posterior eye health by fundus examination using ultrawide fundoscopy
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Color vision
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Contrast sensitivity by Pelli Robson chart
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Multifocal visual evoked potential OR Full field electroretinogram
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Retinal nerve fiber layer (RNFL) by spectral domain optical coherence tomography
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline for Ganglion Cell Layer (GCL) thickness determined by Spectral domain optical coherence tomography
Time frame: Up to 164 Weeks
[All Cohorts] Change from Baseline for Bruch's membrane opening (BMO) disc size, as determined by spectral domain optical coherence tomography
Time frame: Up to 164 weeks
[All Cohorts] Change from Baseline in Mitochondrial function test via flavoprotein fluorescence
Time frame: Up to 164 weeks
[Repeat Dose Cohorts] Plasma concentrations of PYC-001 following multiple dose intravitreally administered PYC-001
Time frame: Up to 164 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Oct 2029, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optic Atrophy, Autosomal Dominant
PYC Therapeutics